On 15 MAY Transcept Pharmaceuticals Inc (NASDAQ:TSPT) announced a special dividend on Wednesday, Investors of record on Monday, May 26th will be paid a dividend of 1.33 per share on Tuesday, June 3rd.Transcept Pharmaceuticals Inc (NASDAQ:TSPT) weekly performance is 5.78%. On last trading day company shares ended up $3.11. Analysts mean target price for the company is $4.10. Transcept Pharmaceuticals Inc (NASDAQ:TSPT) distance from 50-day simple moving average (SMA50) is 2.73%.
On 14 MAY Enzymotec Ltd (NASDAQ:ENZY) reported financial results for the first quarter ended March 31, 2014.Net Revenues Increased 29% to $17.9 Million.Net Income Increased 118% to $5.1 Million, or $0.22 Per Share.(Quarterly Non-GAAP Net Income Increased 135% to $5.6 Million, or $0.24 Per Share).Enzymotec Ltd (NASDAQ:ENZY) shares advanced 8.53% in last trading session and ended the day on $14.00. ENZY Gross Margin is 54.10% and its return on assets is 9.30%. Enzymotec Ltd (NASDAQ:ENZY) quarterly performance is -45.69%.
Insys Therapeutics Inc (NASDAQ:INSY) recently issued a clarifying statement regarding its Subsys(R) (fentanyl sublingual spray) product. Insys takes patient safety very seriously and we are committed to working with physicians to help ensure the proper prescribing and use of our products.Insys Therapeutics Inc (NASDAQ:INSY) shares moved up 11.32% in last trading session and was closed at $26.55, while trading in range of $23.08 – $26.75. Insys Therapeutics Inc (NASDAQ:INSY) year to date (YTD) performance is 2.87%.
StemCells Inc (NASDAQ:STEM) announced that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in two patients have now been observed in two additional patients. StemCells Inc (NASDAQ:STEM) ended the last trading day at $1.41. Company weekly volatility is calculated as 6.77% and price to cash ratio as 2.56. StemCells Inc (NASDAQ:STEM) showed a positive weekly performance of 17.50%.
Mast Therapeutics Inc (NYSEMKT:MSTX) reported fiscal results for the quarter that ended 31 March 2014. In this period, it made good progress across multiple clinical as well as corporate fronts, including its U.S. expansion of the EPIC, the company’s pivotal Phase III study of MST-188 in sickle-cell disease, and the pipeline expansion with acquisition of its AIR001, a clinical-stage-program. Other highlights were the initiation of the Phase II study of its MST-188 in combination with the recombinant tissue-plasminogen activator in the patients suffering from acute limb ischemia, and announced positive non- clinical data in the heart failure. Mast Therapeutics Inc (NYSEMKT: MSTX) weekly performance is 17.54%. On last trading day company shares ended up $0.670. Analysts mean target price for the company is $2.00. Mast Therapeutics Inc (NYSEMKT: MSTX) distance from 50-day simple moving average (SMA50) is 2.07%.